...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.
Reply New Message
Prev Message Back To Forum Threaded View Next Message

"The saga continues"...... Yes, for Resverlogox. 

Zenith on the other hand is doing just fine,..... IMO.

You have a good evening as well fuzzy ..... cheer up. :)

 

Koo

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply